olomorasib
AXP000032.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- Eli Lilly and Company
- Sponsor
- Eli Lilly and Company
Names
Cross-references
- NCI Thesaurus
- C181751
- Wikidata
- Q133445577
- FDA UNII
- C2VJ83PSN7
Approvals
No regulatory approval recorded.
Clinical trials (18)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07890714 | A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] | Recruiting | Phase 1/2 | 2026-10-16 | 2029-09-30 | 268 | Non-small Cell Lung Cancer; Urothelial Cancer |
| NCT07814417 | A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation | Not yet recruiting | Phase 2 | 2026-10 | 2028-11 | 50 | Colorectal Neoplasms |
| NCT07639242 | Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC | Suspended | Phase 2 | 2026-10 | 2030-06-21 | 60 | Locally Advanced NSCLC; Lung Cancer; Lung Cancer (NSCLC); Metastatic NSCLC - Non-Small Cell Lung Cancer |
| NCT07794592 | A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants | Recruiting | Phase 1 | 2026-08-28 | 2026-10 | 24 | Healthy Volunteers |
| NCT07227025 | A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer | Recruiting | Phase 1/2 | 2026-03-03 | 2028-11-30 | 60 | Carcinoma, Non-Small-Cell Lung |
| NCT07439250 | A Study of Olomorasib (LY3537982) in Healthy Participants | Completed | Phase 1 | 2026-03-02 | 2026-04-17 | 15 | Healthy |
| NCT07124013 | A Study of Olomorasib (LY3537982) in Healthy Japanese Participants | Completed | Phase 1 | 2025-09-16 | 2026-01-05 | 191 | Healthy |
| NCT07137689 | A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function | Completed | Phase 1 | 2025-08-18 | 2026-04-10 | 32 | Renal Insufficiency |
| NCT07044271 | A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants | Completed | Phase 1 | 2025-07-11 | 2025-11-08 | 120 | Healthy |
| NCT06890598 | Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Recruiting | Phase 3 | 2025-03-27 | 2029-05 | 700 | Carcinoma, Non-Small-Cell Lung |
| NCT06719128 | A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants | Completed | Phase 1 | 2024-12-06 | 2025-08-25 | 46 | Healthy; Hepatic Insufficiency |
| NCT06235983 | A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors | Completed | Phase 1 | 2024-02-29 | 2025-07-02 | 12 | Advanced Solid Tumors |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Recruiting | Phase 3 | 2023-12-21 | 2027-11 | 1264 | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
| NCT06111521 | A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants | Completed | Phase 1 | 2023-10-27 | 2024-04-01 | 35 | Healthy |
| NCT05901311 | A Study of [14C]-LY3537982 in Healthy Participants | Completed | Phase 1 | 2023-06-05 | 2023-08-10 | 16 | Healthy |
| NCT05860933 | A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants | Completed | Phase 1 | 2023-05-08 | 2023-08-28 | 30 | Healthy |
| NCT05824858 | A Study of the Effect of Food on LY3537982 in Healthy Participants | Completed | Phase 1 | 2023-04-12 | 2023-06-17 | 48 | Healthy |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Active not recruiting | Phase 1/2 | 2021-07-19 | 2027-04 | 540 | Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms |
Recent changes
| Seen | Trial | Change | Detail | Title |
|---|---|---|---|---|
| 2026-11-12 | NCT07890714 | new trial | A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] |
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41319864 | Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2026 | name in title: olomorasib |
| PMID 41820335 | Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. | Nature communications | 2026 | name in title: olomorasib |
| PMID 41940628 | SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. | Future oncology (London, England) | 2026 | cited by trial NCT06119581 |
| PMID 42823821 | SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. | Future oncology (London, England) | 2026 | cited by trial NCT06890598 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41663526 | Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases. | Cancer gene therapy | 2026 | name in abstract: olomorasib |
| PMID 41784211 | A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science. | Cancer investigation | 2026 | name in abstract: olomorasib |
| PMID 42082482 | Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models. | Nature communications | 2026 | name in title: olomorasib |
| PMID 42511798 | KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. | International journal of molecular sciences | 2026 | name in abstract: olomorasib |
| PMID 42551924 | [Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: olomorasib |
| PMID 42622884 | KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: olomorasib |
| PMID 40274247 | KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials. | Critical reviews in oncology/hematology | 2025 | name in abstract: olomorasib |
| PMID 40597785 | The complex journey of targeting RAS in oncology. | BMC cancer | 2025 | name in abstract: LY3537982 |
| PMID 40640254 | Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations. | Scientific reports | 2025 | name in title: LY3537982 |
Notes
KRAS G12C covalent (second generation).
How to cite
olomorasib (AXP000032.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000032.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.